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1. Introduction 
Impaired systolic performance and/or diastolic function have long been detrimental 
consequences of acute myocardial infarction (AMI), which remains a major cause of 
morbidity and mortality worldwide. Despite considerable therapeutic improvements, left 
ventricular dysfunction secondary to infarction continues to pose serious health 
complications, including heart failure (HF), wherein the heart is unable to maintain a cardiac 
output appropriate for the requirements of the body. Several factors contribute to HF, 
including adverse ventricular remodeling, progressive hypertrophy and sustained cell death 
by apoptosis. Therefore, the search for a therapeutic strategy to overcome or mitigate the 
progression of HF is of paramount importance. 
1.1 PDE-5 Inhibitors 
Sildenafil citrate (ViagraTM) is the first PDE-5 inhibitor approved for treatment of erectile 
dysfunction. The discovery of this drug in 1989 was the result of extensive research on 
chemical agents that hold potential promise in the treatment of coronary heart disease. 
Initial clinical studies on sildenafil in the early 1990s were not promising with respect to its 
anti-anginal potential. However, a remarkable side effect was reported by a number of 
volunteers participating in these investigations; sildenafil seemed to enhance penile 
erections, which soon thereafter became the main focus of further studies. More than 10 
million men worldwide have been treated with sildenafil since its market debut in 1998. 
Sildenafil is highly specific for PDE-5 inhibition with relatively minor cross-reactivity with 
PDE-6 (Laties & Fraunfelder, 1999). It has a chemical structure similar to cGMP and inhibits 
PDE-5 by binding to the cGMP-catalytic sites (Corbin & Francis, 2002) thereby allowing the 
accumulation of cGMP in the erectile tissue. Two additional agents in this class (vardenafil 
[LevitraTM] (Porst et al., 2001) and tadalafil [CialisTM]) have also been developed and 
approved by the FDA for treatment of erectile dysfunction and recently sildenafil and 
tadalafil were approved for treatment of pulmonary arterial hypertension (PAH) (Corbin & 
Francis, 2002). PDE-5 inhibitors are structurally similar to cGMP and therefore compete with 
cGMP for binding to PDE-5 at the catalytic site (reviewed in Kukreja et al., 2005). 
Interestingly, PDE expression has been reported to change in pathologic conditions. For 
instance, in patients with cardiovascular disease or diabetes, nitric oxide (NO) levels are 
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suboptimal due to endothelial dysfunction [damaged NO synthase (NOS)], and recently 
myocardial PDE-5 expression has been shown to increase in patients with heart failure 
(Pokreisz et al., 2009). In this regard, targeting PDE-5 is a promising therapeutic approach 
for treatment of cardiovascular disease and dysfunction. 
2. PDE-5 Inhibitors preserve myocardial function following infarction 
A number of pioneering investigations from our laboratory have demonstrated that PDE-5 
inhibitors attenuate ischemic injury in animal and cell models (Ockaili et al., 2002; Salloum 
et al., 2003). In animal models, sildenafil and vardenafil exerted an infarct-sparing effect 
when given before ischemia (Ockaili et al., 2002; Salloum et al., 2003; Salloum et al., 2006) or 
at the time of reperfusion (Salloum et al., 2007). Furthermore, chronic treatment with 
sildenafil immediately after permanent occlusion of the left descending coronary artery 
(LAD) in mice attenuated ischemic cardiomyopathy (Salloum et al., 2008a). These 
cardioprotective effects are mediated by activation of protein kinase G (PKG), increased 
expression of endothelial and inducible nitric oxide synthase (eNOS & iNOS), and 
augmented Bcl-2/Bax ratio. Due to their powerful anti-ischemic effects, PDE-5 inhibitors 
became promising candidates for the preservation of cardiac function following AMI. In 
fact, several studies demonstrated that PDE-5 inhibition preserved left ventricular (LV) 
function in failing hearts as discussed in the following sections. 
2.1 Sildenafil attenuates left ventricular dysfunction in ischemic heart failure 
Salloum et al. showed that chronic treatment with sildenafil preserves cardiomyocytes post 
AMI through reduction of myocardial necrosis, apoptosis and hypertrophy thereby limiting 
the progression of HF (Salloum et al., 2008a). This study used a murine model of post-MI 
remodeling by permanent ligation of the left coronary artery. The experimental protocol is 
illustrated in Figure 1. LV function was assessed at 7 and 28 days post MI. Cardiac function  
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Fig. 1. Experimental protocol illustrating various parameters studied at different time points 
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was evaluated by echocardiography using the Vevo770TM imaging system (VisualSonics, 
Inc., Toronto, Canada). A 30-MHz probe was utilized to obtain two-dimensional, M-mode 
and Doppler imaging from parasternal short-axis view at the level of the papillary muscles 
and the apical four-chamber view (Schiller et al., 1989). M-mode images of the LV were 
obtained and systolic and diastolic wall thickness (anterior and posterior) and LV end-
systolic and end-diastolic diameters (LVESD and LVEDD, respectively) were measured.  
Figure 2 is representative of M-mode images from mice on day 28 post MI. The hearts from 
sham and sildenafil-treated mice exhibited a smaller LV cavity and thicker infarct wall 
compared to the saline-treated mice. Increase in LVEDD, LVESD and a decrease in anterior 
wall diastolic thickness (AWDT), anterior wall systolic thickness (AWST) and fractional 
shortening (FS) in saline- and sildenafil-treated mice (vs. baseline and sham) were observed 
on day 7 and 28.  
Sham 28 days Saline 28 days
1 mm 1 mm
 
Sildenafil 28 days
1 mm
 
Fig. 2. M-mode images from mouse LV treated with sildenafil or vehicle 28 days after MI 
Sildenafil-treated mice had smaller LVEDD, LVESD, greater FS, and lower Tei index 
(reflecting better myocardial performance) on day 7 and 28 as compared to saline-treated 
group (P<0.05, Figure 3). Sildenafil-treated animals also had a shorter isovolumetric 
relaxation time (reflective of lower LV end-diastolic pressure) 28 days after AMI when 
compared to saline-treated animals (11±3 vs. 27±7 ms, respectively, P=0.03), which was not 
different from sham operated animals (10±3, P=NS). AWDT and AWST were also greater in 
sildenafil-treated animals (vs. saline-treated animals, P<0.05) on day 7 and 28 post MI 
showing a protective effect in the peri-infarct region, while no differences in PWDT and 
PWST were seen. Aneurysmatic dilatation of the anterior wall and apex was observed on 
day 28 in 90% of saline-treated mice and 62% of sildenafil treated animals (P>0.05). 
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Moreover, the number of aneurysmatic segments [based on a 16-segment map (Schiller et 
al., 1989)] was 2.9 in saline-treated animals vs. 1.1 in sildenafil-treated animals (P<0.05).  
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Fig. 3. Echocardiography results of LV function at 28 days post-MI in sildenafil- and saline-
treated mice 
2.2 Tadalafil preserves left ventricular function following MI through PKG-dependent 
generation of hydrogen sulfide 
We also studied the effect of a longer acting PDE-5 inhibitor, tadalafil, on cardiac function in 
an acute model of myocardial infarction (Salloum et al., 2009). After baseline transthoracic 
echocardiography, adult male mice were injected i.p. with vehicle (10% DMSO) or tadalafil (1 
mg/kg) with or without KT5823 (KT, PKG blocker, 1 mg/kg) or dl-propargylglycine [PAG, 
Cystathionine-Ǆ-lyase (CSE, H2S-producing enzyme) blocker; 50 mg/kg] 1 h prior to coronary 
artery ligation for 30 min and reperfusion for 24 h, whereas C57BL-wild type and CSE-
knockout mice were treated with either vehicle or tadalafil. After reperfusion, repeat 
echocardiography was performed. Similar to sildenafil, tadalafil preserved cardiac 
performance following MI as compared to vehicle. In this study, since ischemia was limited to 
30 minutes, none of the groups presented with significant LV dilatation at 24 h post infarction, 
however, tadalafil preserved fractional shortening (FS: 31±1.5%) compared to control (FS: 
22±4.8%, P<0.05, Figure 4). Baseline FS was 44±1.7%. KT and PAG abrogated the preservation 
of LV function with tadalafil by a decline in FS to 17±1% and 23±3%, respectively.  
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Fig. 4. Tadalafil preserves LV function at 24 hours following MI through PKG and H2S 
signaling  
2.3 Sildenafil treatment 3 days following MI mitigates the progression of heart failure 
In the previous studies, PDE-5 inhibitors were administered either shortly prior to or 
immediately after infarction. This raises the question whether the preservation of cardiac 
function observed was a true phenomenon, or it was simply secondary to the anti-infarct 
effect of these drugs. Specially, little is known about the effects of PDE-5 inhibition on 
limiting adverse remodeling independent of its ability to modulate infarct size. This concept 
is clinically relevant, particularly in patients with advanced ischemic HF, because necrosis 
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has a negligible role in a post-infarct setting (Anversa et al., 1993). To address this question, 
we administered sildenafil 3 days following MI (Chau et al., 2011). Specifically, we sought to 
determine if sildenafil treatment following LV dysfunction, defined as FS less than 25% at 
day 3 post-MI, could prevent the progression of HF in a permanent LAD occlusion model. 
At 3 days post MI, mice receiving sildenafil or saline (control) treatment had similar FS 
(18±1% and 19±1%, respectively, P>0.05) as compared to baseline value of 47±1%. At days 7 
and 28 post-MI, sildenafil-treated group had a significantly higher FS than saline-treated 
mice (P<0.05). Both LVEDD and LVESD were increased in saline-treated mice as compared 
to sildenafil-treated mice (P<0.05), indicating more dilatation. Moreover, AWDT was greater 
in sildenafil-treated animals versus saline-treated animals (P<0.05) on day 28 post-MI. 
Fractional shortening of sham-operated mice was 43±1.0% at 28 days post left thoracotomy. 
An increase in LVEDD from a baseline value of 3.5±0.1 mm and a decrease in FS in saline- 
and sildenafil-treated mice as compared to baseline and sham-operated mice (P<0.05) was 
observed on days 3 and 28, as shown in figure 5. 
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Fig. 5. Late sildenafil treatment preserves LV function and attenuates the progression of 
ischemic heart failure 
2.4 Sildenafil preserves LV function in infant rabbits 
Although we previously showed that PDE-5 inhibitors induce powerful preconditioning-
like protective effects in the ischemic heart, it is not known whether sildenafil exerts similar 
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protective effects against ischemia/reperfusion injury in the infant rabbit hearts as well. In 
this study, we used the model of coronary artery occlusion and reperfusion in infant rabbits 
(Bremer et al., 2005), which is similar to our previously described adult rabbit model of 
myocardial infarction. The benefits of this work are immense since this model may be 
applicable in pediatrics, and especially in pediatric cardiovascular surgery where there may 
be periods of ischemia/reperfusion injury. Also, we used two-dimensional (2D) and 
Doppler trans-esophageal echocardiography (TEE) for the estimation of LV cardiac output 
(LVCO) and aortic velocity time integral (VTI) in this model. A 10-Fr AcuNav diagnostic 
ultrasound probe (Acuson Corp., Siemens, Iselin, NJ) was inserted into the esophagus, at 
baseline, after the 30 min period of ischemia, and after 3 h of reperfusion in both the control 
and sildenafil groups. Standardized 2D imaging in a long axis view of the LV to show LV 
inflow across the mitral valve and LV outflow tract (LVOT) was obtained. Aortic flow 
Doppler across the aortic valve was performed in a long axis view of the LV and LVOT to 
obtain LVCO. The standard equation: mean velocity (cm/s) × flow area (cm2) × 60 (s/min), 
where mean velocity (cm/s) = VTI (in cm/beat) ÷ RR interval (s/beat), was used to obtain 
LVCO, expressed in milliliters per minute. Laminar Doppler flow across the aortic valve 
confirmed the absence of aortic stenosis. Color Doppler assessment was made of both the 
aortic and mitral valves again in the long axis view at baseline, after the ischemic period, 
and after 3 h of reperfusion for the presence or absence of mitral or aortic regurgitation. 
Subjective functional assessment was also made after ischemia and reperfusion to 
demonstrate at least left ventricular apical diminished contractility to confirm infarction. In 
this study, we showed that both the control and sildenafil-treated groups had comparable 
LVCO and aortic VTI at baseline. The controls had a decline in LVCO and aortic VTI 
immediately after the 30-min period of ischemia (28% and 27% lower than baseline values, 
respectively, p < 0.05), whereas the LVCO and aortic VTI increased in the sildenafil group 
after ischemia (43% and 45% higher than baseline values, respectively, n = 6 per group, p < 
0.05). Both groups, however, had significant decline in LVCO after 3 h of reperfusion (54% 
of baseline in the sildenafil group, p < 0.05, and 62% of baseline in the control group, p < 
0.05), and were not statistically significantly different from each other (n = 4–6 per group). 
Both groups demonstrated a decrease in aortic VTI after 3 h of reperfusion. However, this 
decline was only statistically significant in the control group compared with baseline values. 
None of the rabbits had aortic stenosis or developed aortic regurgitation for the duration of 
the study. Moreover, both the control and sildenafil groups demonstrated a comparable 
amount of mitral regurgitation (no more than mild) after ischemia/reperfusion, and none of 
the rabbits had baseline mitral regurgitation. 
2.5 Sildenafil and vardenafil preserve LV function in female mice 
Since the impact of PDE-5 inhibitors on the female cardiovascular system following 
ischemia remains unknown, we interrogated the effect of sildenafil and vardenafil on 
ischemia/reperfusion injury in female mice. In this study, adult female mice were 
pretreated (ip, bid) with sildenafil (0.7 mg/kg), vardenafil (0.14 mg/kg) or saline one hour 
before left coronary artery ligation for 30 minutes and reperfusion for 24 hours (Salloum et 
al., 2008b). Cardiac function, evaluated using echocardiography, showed that LV end-
diastolic and end-systolic diameters increased 7 days post myocardial infarction with saline 
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(3.5±0.1 mm and 2.4±0.2 mm, respectively). In contrast, no dilatation was detected in 
sildenafil (3.0±0. mm and 1.4±0.1 mm, respectively) and vardenafil (2.9±0.3 mm and 1.4±0.2 
mm, respectively) groups. Fractional shortening decreased at 7 days post infarction with 
saline (30±4%; P<0.05), but was preserved with sildenafil (52±2%) and vardenafil (53±5%). 
These data clearly suggest that PDE-5 inhibitors induce powerful cardioprotection in female 
mice as well. For this reason, PDE-5 inhibition may be a novel therapeutic strategy against 
ischemia/reperfusion injury in women with coronary artery disease. 
3. PDE-5 Inhibitors protect against doxorubicin-induced cardiac dysfunction 
A number of pioneering investigations from our laboratory have demonstrated that PDE-5 
inhibitors attenuate doxorubicin-induced cardiomyopathy in animal and cell models (Koka 
et al., 2010; Das et al., 2010). In a recent study, we tested whether sildenafil potentiates the 
antitumor efficacy of doxorubicin in prostate cancer. Our results show that doxorubicin and 
sildenafil induce a potent antitumor effect in prostate cancer while simultaneously 
providing a cardioprotective effect. This study was an elegant sequel to our previous work 
demonstrating that sildenafil attenuated doxorubicin-induced cardiomyopathy in mice 
(Fisher et al., 2005). In that study, we showed that treatment with sildenafil attenuates the 
decline in LV developed pressure caused by doxorubicin treatment. An important question, 
however, was whether sildenafil interferes with the anti-tumor effect of doxorubicin. Our 
recent study showed that sildenafil ameliorates doxorubicin-induced cardiac dysfunction 
without interfering with its chemotherapeutic benefits (Das et al., 2010). Cardiac function in 
nude mice with tumor xenografts was monitored by Doppler echocardiography using the 
Vevo770 imaging system (VisualSonics, Toronto, Canada) as previously reported (Salloum 
et al., 2008a). A slight increase in LVEDD and LVESD were observed with doxorubicin. 
LVFS and LVEF declined in doxorubicin-treated mice. Sildenafil co-treatment with 
doxorubicin improved LVFS and LVEF compared with the doxorubicin-treated group (P < 
0.05). No differences in heart rate were observed between control, doxorubicin, and 
doxorubicin and sildenafil groups. Sildenafil-treated animals showed lower heart rates 
compared with other groups (P < 0.01; n = 8). These data suggest that changes in LVFS or 
LVEF were independent of heart rate.  
In a separate study, tadalafil improved left ventricular function and prevented 
cardiomyocyte apoptosis in doxorubicin-induced cardiomyopathy through mechanisms 
involving upregulation of cGMP, PKG activity, and MnSOD level without interfering with 
the chemotherapeutic benefits of doxorubicin (Koka et al., 2010). In these studies, adult male 
CF-1 mice were randomized to receive saline (0.2 ml i.p.), doxorubicin (15 mg/kg i.p.), or 
doxorubicin + tadalafil (4 mg/kg p.o. daily) for 9 days starting 3 days before doxorubicin 
treatment. We chose to use a single dose of doxorubicin at 15 mg/kg i.p., which has been 
reported to be cardiotoxic. LV function was significantly impaired 5 days after doxorubicin 
treatment. However, mice treated with doxorubicin + tadalafil showed preserved fractional 
shortening and ejection fraction compared with those treated with doxorubicin as shown in 
Figure 6 (n = 6, p < 0.05). In addition, the LV systolic pressure decreased 36%, +dp/dtmax 
decreased 63%, −dp/dtmax decreased 57%, and heart rate decreased 30% as compared with 
the controls (P < 0.05). In contrast, mice treated with doxorubicin + tadalafil showed improved 
LV function (i.e., LV systolic pressure, 33%; +dp/dtmax, 35%; −dp/dtmax, 46%, and heart 
rate, 27%) as compared with the group treated with doxorubicin alone (n = 6, p < 0.05). 
www.intechopen.com
 Phosphodiesterase-5 Inhibitors Improve Left Ventricular Function in Failing Hearts 
 
105 
 
Fig. 6. Tadalafil attenuates doxorubicin-induced LV dysfunction 
4. PDE-5 inhibitors protect against hypertrophy-induced cardiac dysfunction 
Sustained pressure overload leads to cellular and molecular changes that are initially 
activated as compensatory mechanisms but later become maladaptive and contribute to 
progressive cardiac dysfunction and heart failure. This response involves a combination of 
complex signaling and transcription pathways that induce hypertrophic remodeling (Frey & 
Olson, 2003; Frey et al., 2004). The heart appears to have an intrinsic signaling system 
coupled to cGMP that can inhibit myocardial proliferative responses. Several studies using 
approaches that involve enhanced cGMP synthesis or prevention of its degradation have 
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been shown to blunt hypertrophy despite sustained pressure overload or neurohormonal 
stress. Interestingly, although cGMP synthesis is often increased by chronic exposure to 
such stresses, this increase appears to be ineffective to impede hypertrophy and remodeling 
progression, likely due to increase in PDE-5 expression and activity that accompany such 
stressors. For this reason, the use of PDE-5 inhibitors to reduce the catabolism may augment 
cGMP-dependent antihypertrophic effects. In the study by Takimoto et al., the authors show 
that PDE-5 inhibition with sildenafil prevents cardiac chamber, cellular and molecular 
remodeling induced by pressure overload (Takimoto et al., 2005). They next tested a more 
clinically relevant question of whether inhibition of PDE-5 can reverse pre-existing 
hypertrophy. Mice were exposed to transverse aortic constriction for 7–10 days, which 
increased heart mass by 63% (P < 0.005) without chamber dilatation. After hypertrophy was 
established, these mice were divided into 2 groups that received either sildenafil or vehicle for 
an additional 2 weeks. Cardiomyocyte hypertrophy and interstitial fibrosis were observed in 
mice exposed to 1 week of transverse aortic constriction, and both reversed to baseline with 
sildenafil treatment. Serial echocardiography also showed a gradual decline in LV mass and 
wall thickness, with preservation of systolic ejection in sildenafil-treated mice (Figure 7).  
 
Fig. 7. Sildenafil attenuates and reverses hypertrophy-induced cardiac dysfunction  
Another study by Nagayama et al. showed that delayed sildenafil treatment suppresses 
progressive cardiac dilatation, dysfunction, fibrosis, and hypertrophy in hearts subjected to 
sustained pressure-overload (Nagayama et al., 2009). In this study, following 3-week 
transverse aortic constriction, hearts had a +135% increase in LV mass, chamber end-systolic 
(+91%) and end-diastolic (+10%) dimensions, and reduced fractional shortening (−42%). 
Subsequent treatment with sildenafil fully arrested progressive remodeling, whereas control 
hearts further dilated and hypertrophied after 9-week transverse aortic constriction. Post-
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mortem analysis confirmed that both heart and lung weights, normalized to tibia length, 
were lower with sildenafil treatment. Moreover, cardiomyocyte cross-sectional dimension 
and interstitial and perivascular fibrosis was also reduced in sildenafil-treated myocardium. 
5. PDE-5 inhibitors reverse cardiac dysfunction in Duchenne muscular 
dystrophy 
Duchenne muscular dystrophy (DMD) is a degenerative, muscle-wasting disease caused by 
mutations in the dystrophin gene. The total loss of dystrophin mainly affects skeletal muscle 
and results in impaired respiratory function, primarily in older boys (Finsterer & 
Stöllberger, 2003; Adamo, 2010). Due to remarkable improvement of noninvasive 
respiratory support in the recent past, the lifespan of patients with DMD has increased. 
Unfortunately, this was also associated with an increase in the incidence of complications 
and eventual mortality from cardiomyopathy (McNally, 2008). Cardiomyopathy is a 
delayed symptom of the disease that usually develops by the second decade of life, with 
more than 90% of patients presenting clinical symptoms by 18 y of age (Finsterer & 
Stöllberger, 2003). Loss of cardiac dystrophin eventually leads to dilated cardiomyopathy, 
which manifests as congestive heart failure in at least 20% of patients (Finsterer & 
Stöllberger, 2003). Current treatment options for heart failure associated with DMD include 
angiotensin converting enzyme inhibitors and ǃ-blockers. Despite the moderate benefits 
provided by these medications in patients with systolic heart failure, similar advantages 
have not been observed in dystrophic patients with features of systolic and diastolic 
dysfunction (Bushby, 2003). These findings highlight the need for treatments that slow the 
development of cardiomyopathy in DMD and improve cardiac function in older patients 
with established cardiomyopathy.  
It has been shown that stimulation of cGMP synthesis by overexpression of cardiac-specific 
neuronal (n)NOS reduces impulse-conduction defects in dystrophin-deficient (mdx) mice 
(Wehling-Henricks et al., 2005; Wehling et al., 2001). Similarly, increased particulate 
guanylyl cyclase activity in young mdx mice has also been shown to decrease susceptibility 
to cardiac damage during sympathetic stress (Khairallah et al., 2008). These findings clearly 
implicate reduced NO-cGMP signaling as a key contributor to myocardial pathogenesis in 
patients with DMD. Therefore, it is plausible that restoration of NO signaling, particularly 
by preservation of cGMP, may provide therapeutic benefit to dystrophic hearts. In a recent 
study, Adamo et al. tested whether chronic inhibition of PDE-5 with sildenafil would 
reverse cardiac dysfunction in the mdx mouse model of DMD (Adamo et al., 2010)  
Chronic sildenafil treatment prevented LV functional deficits in aging mdx mice. 
Furthermore, late sildenafil treatment, i.e. after developing cardiomyopathy, reversed the 
established symptoms.  
Conventional echocardiography and tissue Doppler analysis were used to monitor the 
development of LV dysfunction in aging mdx mice. Both the myocardial performance index 
(MPI) and ratios of early diastolic velocity (Ea) to peak velocity with atrial contraction (Aa) 
were calculated. MPI is a sensitive measure of left ventricular systolic and diastolic 
performance, whereas the Ea/Aa largely reflects diastolic function. The majority of patients 
with DMD exhibit diastolic dysfunction and impaired myocardial performance, which can 
be identified by increased MPI (Bahler et al., 2005). This dysfunction usually precedes the 
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onset of systolic heart failure and dilated cardiomyopathy (Markham et al., 2006). Mdx mice 
show these same echocardiographic abnormalities (Jearawiriyapaisarn et al., 2010; 
Townsend et al., 2007).  
Three different sildenafil treatment regimens were used: 1- long-term chronic sildenafil 
treatment starting at 1 month of age, 2- long-term treatment starting at 12 months with 
echocardiographic measurements taken 3 months later to assess whether established 
dysfunction could be reversed, and 3- a similar treatment starting at 12 months, but with 
multiple measurements to determine the time course of the reversal. The results showed 
impaired LV performance in mdx mice (increased MPI) by 11 to 13 months of age compared 
with treated and untreated WT controls. As mice approached 15 months of age, mdx mice 
continued to demonstrate impaired LV function whereas WT control mice began to show a 
slight age-related decline in cardiac performance. Although sildenafil did not have an effect 
on cardiac performance in WT mice, mdx mice that received chronic sildenafil treatment 
starting at 1 month of age retained a relatively normal MPI with age, indicating that 
sildenafil attenuated the cardiomyopathy in mdx mice. Furthermore, late sildenafil 
treatment following well-established cardiomyopathy at 12 months of age completely 
reversed LV dysfunction by age 15 months, as evidenced by normal MPI at that time point. 
Taken together, these results demonstrate that chronic treatment with sildenafil mitigates 
the progression of LV dysfunction and late treatment also reverses established LV 
dysfunction in mdx mice (Figure 8). 
In order to better understand the underlying cause for the improvement in the MPI by 
sildenafil, which could be a result of effects on systolic or diastolic function, the authors 
measured the Ea/Aa using tissue Doppler imaging to more directly evaluate diastolic 
function in mdx mice. This parameter largely reflects the diastolic (chamber relaxation and 
filling) capacity of the LV. As shown in Figure 8B, diastolic dysfunction (indicated by Ea/Aa 
<1) was observed in mdx mice as early as 8 months of age. Moreover, chronic sildenafil 
treatment reduced the progression of diastolic dysfunction in mdx mice through 15 months 
of age. Even when sildenafil treatment was initiated after LV dysfunction was established at 
12 months of age, it markedly reversed the diastolic dysfunction within 3 months. Based on 
this result, the authors suggest that diastolic dysfunction is a major component of the 
impaired MPI observed in 11- to 13-month-old mdx mice.  
Cardiac remodeling after injury can result in hypertrophy, increased fibrosis and systolic 
dysfunction of the heart. However, cardiomyopathy in mdx mice is characterized by slow, 
progressive cell death, followed by compensatory hypertrophy of the surviving 
cardiomyocytes. In order to study the impact of sildenafil on cardiac dimensions and 
remodeling, the authors used M-mode echocardiography to determine LV dimensions in 
conscious mdx mice. By 12 months of age, the LV wall thickness of mdx mice was increased 
and the LV mass index (LVMI) was larger compared with sildenafil-treated mdx mice. 
Taken together, the anti-hypertrophic effect of sildenafil, coupled with the prevention of 
diastolic dysfunction, suggest that sildenafil may also have protective effects on some 
aspects of cardiac remodeling. However, the authors did not find any difference in the FS of 
12-month-old, conscious mdx mice compared with WT controls or sildenafil-treated mdx 
mice, nor did they observe any effect on heart rate. This indicates a lack of major systolic 
dysfunction in these animals up to 12 month of age. Although systolic dysfunction may 
develop later in life, it appears that diastolic dysfunction plays a more prominent role in the 
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cardiomyopathy seen in the mdx mice used in this study.Overall, the findings of this study 
suggest that PDE-5 inhibitors may be an effective treatment for DMD-associated 
cardiomyopathy at early and late stages of the disease. 
  
Fig. 8. Sildenafil reverses cardiac dysfunction in the mdx model of Duchenne Muscular 
Dystrophy 
6. Clinical use of PDE-5 inhibitors in patients with heart failure 
Following years of basic research examining the cardioprotective effects of PDE-5 inhibitors 
against ischemia, a recent study by Guazzi et al. demonstrated that sildenafil improves LV 
diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart 
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failure (Guazzi et al., 2011). The study primarily focused on the effects of chronic PDE-5 
inhibition on LV diastolic function and cardiac chamber remodeling, providing the first 
human evidence that PDE-5 inhibition can be beneficial for improving the diastolic and 
structural properties of the failing LV. Transthoracic echocardiography was performed using 
IE33, Philips ultrasound machine, equipped with a software for tissue Doppler (TD), using a 
2.5- to 5.0-MHz probe (S5). Standard M-mode, 2D, and Doppler blood flow measurements 
were performed according to the current American Society of Echocardiography Guidelines 
(Quiñones et al., 2002). Chamber dimensions were obtained using standard procedures 
including left atrial volume index (LAVI) and LV mass index (LVMI) (Devereux & Reichek, 
1977). Septal and posterior wall thickness, LA, and LV end-systolic and end-diastolic 
dimensions were obtained from the parasternal long-axis view. LVEF, end-diastolic volume 
index (LVEDVI), and end-systolic volume index were evaluated with the Simpson method. 
Interestingly, E/E′, a variable repeatedly found related to LV filling pressures in a variety of 
left-sided cardiac disorders (Lester et al., 2008), significantly decreased at 6 months and 1 
year of active treatment (Figure 9). Additional study findings that support the hypothesis 
that PDE-5 inhibition may represent a novel and viable therapeutic strategy for improving 
LV relaxation were the significant shortening in both lateral and septal T E-E′, a Doppler-
derived index of LV relaxation performance validated against invasively measured negative 
dP/dT22, and the reverse remodeling effect on LV mass. Moreover, over 12 months, LAVI, 
LVEDV, and LVMI were unchanged in the placebo group and decreased in the active 
treatment group, which suggests reverse remodeling with sildenafil involving both the 
ventricle and the atrium. Over the same time period in the sildenafil group, there was a 
progressive increase in mean LVEF, from 29.5% at baseline to 34.9% and 36.3% at 6 and 12 
months, respectively (P<0.01). Changes observed with sildenafil were significantly different  
  
Fig. 9. Sildenafil significantly decreased E/E′ at 6 months and 1 year of active treatment in 
patients with stable systolic heart failure 
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compared with placebo (P<0.01). Additionally, diastolic measures of LV function 
demonstrated systematic and sustained improvement after both 6 months and 1 year of 
sildenafil treatment. The transmitral E/A ratio, isovolumic relaxation time, and both lateral 
and septal E/E′ decreased from baseline through 12 months (all P<0.01), which is indicative 
of an improvement in LV diastolic function and a decrease in LV filling pressure.  
Furthermore, septal T E-E′ was significantly reduced at 6 and 12 months of sildenafil 
treatment (P<0.01). All these changes were in agreement with the observed reverse 
remodeling on LAVI, which is viewed as morphological expression of LV end-diastolic 
pressure (Lester et al., 2008). Changes observed at 6 months and 1 year after sildenafil were 
significantly different compared with the placebo group (P<0.01).  
7. Concluding remarks 
With the advancement in the management of patients with cardiovascular disease and 
improvement in survival following cardiovascular events, the incidence of heart failure, 
especially in patients of age 65 and older is increasing. Using state-of-the-art 
echocardiography, we and others have demonstrated that treatment with PDE-5 inhibitors 
improve LV function in various models of myocardial dysfunction and heart failure. These 
studies suggest that PDE-5 inhibitors are immensely promising for further development as 
novel drug therapies for myocardial infarction, LV hypertrophy and dysfunction, 
doxorubicin-induced cardiotoxicity, and heart failure. Clinical studies of sildenafil on heart 
failure patients have reported improved exercise capacity, coupled with reduced pulmonary 
vascular resistance and better endothelial function (Lewis et al., 2007; Guazzi et al., 2007). 
Sildenafil also preserved LV function in patients with heart failure due to various etiologies 
(Guazzi et al., 2011). Several other studies indicated that PDE-5 inhibition with sildenafil has 
a therapeutic promise for stroke, neurodegenerative diseases and potentially other 
circulatory disorders (reviewed in Kukreja et al., 2007; Kukreja et al., 2011a; Kukreja et al. 
2011b). These drugs may not only delay or reduce the pathological damage or defects in 
various vital organs, but also improve the overall well-being and quality of life in patients. 
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